Table 3.
Association of aberrant DNA methylation and clinical outcome in OPSCC patients
| Gene | Hyper-/hypomethylation | Cohort | Clinical outcome | References |
|---|---|---|---|---|
| MGMT | Hyper | 88 OPSCC | Poorer PFS and OS | [45] |
| ALDH3A1 | Hyper | 76 HNSCC, including 15 OPSCC | Decreased OS | [172] |
| TAP1 | Hyper | |||
| SMG1 | Hypo | 40 OPSCC | Improved OS in HPV-positive OPSCC | [153] |
| ALDH1A2 | Hypo | 170 OPSCC (3 independent cohorts) | Improved clinical outcome in HPV-positive OPSCC | [154] |
| GATA4 | Hyper | |||
| GRIA4 | Hyper | |||
| IRX4 | Hyper | |||
| OSR2 | Hypo | |||
| DAPK1 | Hyper | 70 HNSCC, including 9 OPSCC | Lymph node metastasis | [173] |
| MGMT | Hyper | |||
| WIF1 | Hyper | 43 HNSCC, including 19 OPSCC | Decreased OS | [54] |
| GALR1/2 | Hyper | 202 HNSCC, including 58 OPSCC | Poor survival with the highest association in HPV-negative OPSCC | [174] |
| LINE-1 | Hypo | 110 OPSCC (2 independent cohorts) | Increased risk of early relapse in HPV-negative OPSCC | [60] |
ALDH aldehyde dehydrogenase, DAPK death-associated protein kinase, GALR galanin receptor, GATA GATA binding protein, GRIA glutamate receptor, IRX iroquois homeobox, LINE long interspersed nuclear element, MGMT O-6-methylguanine-DNA methyltransferases, OSR odd-skipped-related, SMG nonsense mediated mRNA decay associated PI3K-related kinase, TAP transporter associated with antigen processing, WIFI WNT inhibitory factor